Cardiol Therapeutics (CRDL)
(Real Time Quote from BATS)
$1.12 USD
-0.23 (-17.04%)
Updated Aug 6, 2025 12:56 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRDL 1.12 -0.23(-17.04%)
Will CRDL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?
Other News for CRDL
Roth bullish on Cardiol, says trial results enough to attract larger partner
Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements
Cardiol falls 14% to $1.16 after myocarditis study results
Cardiol ARCHER study not statistically significant, says Canaccord
Cardiol ARCHER study not statistically significant, says Canaccord